Annual Report

Overview

The report delivered strong FY20 growth, with consolidated revenue of ₹230,985.1 million and a global workforce of approximately 23,000 people. It invested ₹9,580 million in R&D across its pharmaceutical portfolio and expanded specialty, vaccine and biologics capabilities. The report also details extensive COVID-19 continuity, employee-safety and community-relief measures. Environmental initiatives included solar generation, energy conservation and carbon-emission avoidance.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2020
Period: 1 April 2019 – 31 March 2020
Publication date: 3 June 2020
Language: English
Pages
File size

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services